In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smear Campaign

Executive Summary

Pap smears, unlike most other high-volume tests, are manual, subjecting them to human error and inexact judgments. To offset these deficiencies, scientists have been working for nearly three decades to develop automated screening systems, endeavors that until recently were littered with failures.

You may also be interested in...



VisionGate Inc.

In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.

VisionGate Inc.

In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.

Exact Sciences' Moment

Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel